

Preparing for the future: Radioligand therapy as an essential pillar in Oncology



**Saturday, 14 September 2024,
13:00 – 14:30 CEST**

Oviedo Auditorium, Hall 3,
Fira Barcelona Gran Via, Barcelona, Spain



Leonhard Schaetz
(moderator)
Novartis Pharma AG



Elena Castro
Hospital Universitario
12 de Octubre



Erik Briers
Europa UOMO



Ken Hermann
Universitätsmedizin
Essen



Désirée Deandreis
Institut Gustave
Roussy

- **Introduction to Healthcare System (HCS) Readiness for Radioligand Therapies (RLT) in Oncology**
Leonhard Schaetz, Novartis
- **Panelists' Insights: Multi-stakeholder Perspectives on Overcoming Barriers to Establishing RLT in Oncology**
Ken Hermann, Erik Briers, Elena Castro, Désirée Deandreis
- **Multi-stakeholder Panel Discussion: A Multidisciplinary Approach to Navigating Challenges and Embracing Opportunities to Unlock HCS Readiness for RLT**
All
- **Open Forum: Q&A Session**
All
- **Closing Remarks: Final Thoughts**
All

Symposium is organized and funded by Novartis in the context of ESMO 2024 in Spain. This scientific program and/or material was developed for use outside of the US and UK, intended for non-US and non-UK HCPs, and is to be used in accordance with local laws and regulations. The aim of this medical symposium is scientific, educational and not promotional. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.